Selinexor for the treatment of patients with previously treated multiple myeloma
Expert Rev Hematol. 2021 May 14. doi: 10.1080/17474086.2021.1923473. Online ahead of print.ABSTRACTINTRODUCTION: : Multiple myeloma (MM) is an increasingly treatable but still incurable hematologic malignancy. Prognosis has improved significantly over recent years, although further advances remain urgently needed, especially for patients with heavily pre-treated and resistant disease for whom there are limited options. Selinexor is a first-in-class, oral, selective inhibitor of nuclear export (SINE) compound that triggers apoptosis in malignant cells by inducing nuclear retention of oncogene messenger RNAs (mRNAs) and reac...
Source: Expert Review of Hematology - May 14, 2021 Category: Hematology Authors: Clifton C Mo Sundar Jagannath Ajai Chari Ajay K Nooka Sagar Lonial David Siegel Noa Biran Cristina Gasparetto Nizar J Bahlis Paul G Richardson Source Type: research

Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis
Conclusion: DOACs are associated with only a modest reduction in stroke or systemic embolism, major bleeding, and mortality when compared to VKA in CKD patients. Reduction in mortality and major bleeding with DOAC may only be seen in moderate-to-severe CKD patients.PMID:33949923 | DOI:10.1080/17474086.2021.1920012 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - May 5, 2021 Category: Hematology Authors: Rongfang Xu Fan Wu Jiarong Lan Peixin Duan Source Type: research

Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings
Expert Rev Hematol. 2021 May 4. doi: 10.1080/17474086.2021.1923475. Online ahead of print.ABSTRACTINTRODUCTION: : Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has resulted in increased levels of disease-free survival in severe aplastic anemia (SAA). Haploidentical transplantation (haplo-SCT) was previously not recommended due to unacceptable incidences of graft-versus-host disease (GvHD) and graft failures. With the advent of intensive GvHD prophylaxis strategies, the outcomes obtained with haplo-SCT for SAA have gradually improved.AREAS COVERED: : A comprehensive search considered PubMed reported article...
Source: Expert Review of Hematology - May 4, 2021 Category: Hematology Authors: Zheng-Li Xu Xiao-Jun Huang Source Type: research

An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
Expert Rev Hematol. 2021 May 4. doi: 10.1080/17474086.2021.1924052. Online ahead of print.ABSTRACTINTRODUCTION: Despite therapeutic advances, myeloma remains an essentially incurable disease, with a median survival of approximately 8 -10 years. Most patients will develop disease that is refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), and treatment regimens containing drugs with different mechanisms of action are necessary. Isatuximab is one such novel agent, an anti-CD38 monoclonal antibody (MoAb), and is the second drug in this class after daratumumab. This paper will consider the current ro...
Source: Expert Review of Hematology - May 4, 2021 Category: Hematology Authors: Anna Piggin H Miles Prince Source Type: research

Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia
This article covers the diagnosis, definitions, and clinical challenges of CIT, and then focuses on the therapeutics developed to manage CIT. The first-generation thrombopoietic agents (oprelvekin and recombinant human thrombopoietins) are reviewed for critical background and context, followed by a detailed discussion of the data for the thrombopoietin receptor agonists (TPO-RAs) to manage CIT. Efficacy of TPO-RAs in treatment and prevention of CIT, as well as safety concerns such as the risk of thromboembolic complications, are reviewed in detail. For this review, a PubMed/MEDLINE literature search was undertaken for rele...
Source: Expert Review of Hematology - April 30, 2021 Category: Hematology Authors: Hanny Al-Samkari Gerald A Soff Source Type: research

Consanguineous marriage and rare bleeding disorders
Expert Rev Hematol. 2021 Apr 29. doi: 10.1080/17474086.2021.1923476. Online ahead of print.ABSTRACTINTRODUCTION: Rare bleeding disorders (RBDs) are a heterogeneous group of bleeding disorders. Consanguineous marriage is the favorite partnership in many communities among more than a billion population. Consanguineous marriages allow the defective recessive genes in RBDs to remain in the family. Clinical approach to RBDs is not as straightforward as typical bleeding disorders, which are secondary to scarcity and variation of RBDs. However, in many developing countries, the limitations of diagnostic facilities, the supply of ...
Source: Expert Review of Hematology - April 29, 2021 Category: Hematology Authors: Hassan Mansouritorghabeh Source Type: research

Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia
Expert Rev Hematol. 2021 Apr 28. doi: 10.1080/17474086.2021.1924054. Online ahead of print.ABSTRACTINTRODUCTION: The new World Health Organization (WHO) guidelines on physical activity incorporate new concepts, such as sedentary behavior, recommendations for specific age groups and for people living with chronic conditions and disability. This could be extrapolated for the first time to people with hemophilia (PWH) within the framework in which these recommendations are applicable. The benefits of physical activity for PWH include physical, psychological and social benefits.AREAS COVERED: This is a narrative review of the ...
Source: Expert Review of Hematology - April 28, 2021 Category: Hematology Authors: Hortensia De la Corte-Rodr íguez E Carlos Rodr íguez-Merchán M Teresa Alvarez-Rom án Victor Jim énez-Yuste Source Type: research

Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines
Expert Rev Hematol. 2021 Apr 28. doi: 10.1080/17474086.2021.1923474. Online ahead of print.ABSTRACTIntroduction: Some patients with positive antiphospholipid antibodies (aPL) have not been included in randomized clinical trials or observational registries and, therefore, information on their risk of obstetric or thrombotic recurrence and optimal treatment is scarce.Areas covered: In the present review, the existing evidence regarding the management of two laboratory scenarios not covered by the guidelines is presented: (1) patients with antiphospholipid syndrome (APS) clinical manifestations and aPL positivity not fulfilli...
Source: Expert Review of Hematology - April 28, 2021 Category: Hematology Authors: Gilberto Pires da Rosa Ignasi Rodr íguez-Pintó Gerard Espinosa Source Type: research

Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia
Expert Rev Hematol. 2021 Apr 28. doi: 10.1080/17474086.2021.1924054. Online ahead of print.ABSTRACTINTRODUCTION: The new World Health Organization (WHO) guidelines on physical activity incorporate new concepts, such as sedentary behavior, recommendations for specific age groups and for people living with chronic conditions and disability. This could be extrapolated for the first time to people with hemophilia (PWH) within the framework in which these recommendations are applicable. The benefits of physical activity for PWH include physical, psychological and social benefits.AREAS COVERED: This is a narrative review of the ...
Source: Expert Review of Hematology - April 28, 2021 Category: Hematology Authors: Hortensia De la Corte-Rodr íguez E Carlos Rodr íguez-Merchán M Teresa Alvarez-Rom án Victor Jim énez-Yuste Source Type: research

Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients
Conclusion: A statistically significant association was demonstrated between PPI treatment and the development of febrile neutropenia among hemato-oncological patients. The clinical implications necessitate further caution in administering PPIs to patients with hematological malignancy receiving chemotherapy.PMID:33899663 | DOI:10.1080/17474086.2021.1920011 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - April 26, 2021 Category: Hematology Authors: Rawi Hazzan Usama Darawsha Ziv Neeman Ariel Aviv Source Type: research

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Expert Rev Hematol. 2021 Apr 8:1-13. doi: 10.1080/17474086.2021.1909469. Online ahead of print.ABSTRACTINTRODUCTION: Survival in multiple myeloma (MM) has improved due to the ongoing revolution of therapeutic approaches. Nevertheless, many patients relapse, and additional novel approaches are required to prolong remissions and prevent disease progression.AREAS COVERED: Considering the success of monoclonal antibodies (mAbs) against CD38 and SLAMF7 in relapsed/refractory MM (R/R MM), additional antigens expressed on malignant plasma cells are being investigated as treatment targets. Among these, many trials are focusing on ...
Source: Expert Review of Hematology - March 26, 2021 Category: Hematology Authors: Marc Braunstein Jonathan Weltz Faith Davies Source Type: research

A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Expert Rev Hematol. 2021 Mar 26. doi: 10.1080/17474086.2021.1909469. Online ahead of print.ABSTRACTINTRODUCTION: : Survival in multiple myeloma (MM) has improved due to the ongoing revolution of therapeutic approaches. Nevertheless, many patients relapse, and additional novel approaches are required to prolong remissions and prevent disease progression.AREAS COVERED: Considering the success of monoclonal antibodies (mAbs) against CD38 and SLAMF7 in relapsed/refractory MM (R/R MM), additional antigens expressed on malignant plasma cells are being investigated as treatment targets. Among these, many trials are focusing on B ...
Source: Expert Review of Hematology - March 26, 2021 Category: Hematology Authors: Marc Braunstein Jonathan Weltz Faith Davies Source Type: research

How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies
Expert Rev Hematol. 2021 Mar 25. doi: 10.1080/17474086.2021.1909468. Online ahead of print.ABSTRACTIntroduction: MALT (mucosa associated lymphoid tissue) lymphoma is a distinct type of B-cell lymphoma characterized by extranodal manifestation and an indolent clinical course with 10-year survival rates up to 90%. However, transformation to aggressive lymphoma may occur and treatment is indicated in case of symptomatic or progressive disease.Areas covered: This review covers clinical and biological features potentially related to prognosis and outcome of MALT lymphoma patients, as well as available prognostic tools and risk ...
Source: Expert Review of Hematology - March 25, 2021 Category: Hematology Authors: Barbara Kiesewetter Markus Raderer Source Type: research

Diagnostic and therapeutic challenges in hairy cell leukaemia-variant: where are we in 2021?
Expert Rev Hematol. 2021 Mar 24. doi: 10.1080/17474086.2021.1908121. Online ahead of print.ABSTRACTINTRODUCTION: Hairy cell leukemia-variant (HCL-V) is a rare B-cell neoplasm arising or homing primarily in the spleen. It has been considered in the WHO classification of Haemopoietic and Lymphoid Tumours as a provisional entity since 2008 and included under the umbrella of unclassifiable splenomegalic B-cell leukemia/lymphomas. The diagnosis is a challenge to haematopathologists and management of these patients by the clinicians is difficult due to the lack of diagnostic and therapeutic guidelines and prospective studies.ARE...
Source: Expert Review of Hematology - March 24, 2021 Category: Hematology Authors: Estella Matutes Source Type: research

Computational modelling - an approach to the development of blood grouping reagents
Expert Rev Hematol. 2021 Mar 24. doi: 10.1080/17474086.2021.1908119. Online ahead of print.ABSTRACTBlood group antigens are defined by an immune response that generates antibodies against a red blood cell molecule. Antibodies against these antigens can be associated with haemolytic transfusion reactions. However, difficulties can arise when developing antibodies against antigens through the use of peptide sequences alone. Three-dimensional representations (models) of the molecular structure of antigen-bearing proteins can provide valuable insights into tertiary structures and their consequent antigenicity. This can be achi...
Source: Expert Review of Hematology - March 24, 2021 Category: Hematology Authors: Serena Ekman Robert Flower Ross T Barnard Alison Gould Xuan T Bui Source Type: research

Hematological manifestations and complications of Gaucher disease
Expert Rev Hematol. 2021 Mar 24. doi: 10.1080/17474086.2021.1908120. Online ahead of print.ABSTRACTIntroduction: Gaucher disease (GD), although pan-ethnic and rare (common in Ashkenazi Jews), is of great importance to hematologists both for diagnosis and management. The need for increased awareness of GD is that delayed diagnosis may lead to preventable irreversible complications (mainly skeletal) or unnecessary invasive procedures (e.g., bone marrow biopsy), and the birth of another affected sibling due to lack of genetic consulting.AREAS COVERED: : The review outlines the common hematological manifestations of GD, includ...
Source: Expert Review of Hematology - March 24, 2021 Category: Hematology Authors: Shoshana Revel-Vilk Jeff Szer Ari Zimran Source Type: research